New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
10:25 EDTMYLMylan receives final approval from FDA for ANDA for generic Maxalt MLT tablets
Mylan announced that its subsidiary Mylan Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Applications for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg, and Rizatriptan Benzoate Tablets, 5 mg and 10 mg. These products are the generic versions of Merck's Maxalt MLT Tablets and Maxalt Tablets, respectively, and are indicated for the acute treatment of migraine with or without aura in adults.
News For MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
07:45 EDTMYLFDA to hold a public meeting
Subscribe for More Information
07:25 EDTMYLTeva appears to be weighing transformative deal, says Bernstein
After attending Teva's (TEVA) meeting with investors, Bernstein thinks that the company is considering making a 'transformative' acquisition, although it believes that such a deal may not be imminent. The firm sees Mylan ((MYL) and the generic units of Actavis (ACT), Pfizer (PFE), and possibly Valeant (VRX) as the four logical candidates. It says that Teva can pay $81 per share for Mylan, and that a takeover of Mylan would raise Teva's EPS to about $6.50 in 2017 and $7 in 2018. Bernstein raised its price target on Teva to $69 from $60 and keeps an Outperform rating on the shares.
March 17, 2015
08:34 EDTMYLInSite Vision announces settlement of lawsuit against Mylan
Subscribe for More Information
March 16, 2015
10:28 EDTMYLOptions with increasing implied volatility
Options with increasing implied volatility: PVA NFLX BMRN DNOW MYL TEVA PEP GE

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use